Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

NCT02650414 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT02650414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02650414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 13, 2016
Completion date
December 31, 2037
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell leukemias, b cell lymphomas